Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H36O5 |
| Molecular Weight | 356.4968 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@H](O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
InChI
InChIKey=DPOINJQWXDTOSF-DODZYUBVSA-N
InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h15-17,19,21,23H,2-14H2,1H3,(H,24,25)/t15-,16+,17+,19+/m0/s1
| Molecular Formula | C20H36O5 |
| Molecular Weight | 356.4968 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
13,14-dihydro-prostaglandin E1 (dihydroprostaglandin E1 or 13,14-dihydro-PGE) is a biologically active metabolite of prostaglandin E1. It inhibits adenosine triphosphate (ATP) release and thromboxane generation by human platelets. Besides, the reduced influx of LDL cholesterol into the rabbit aorta after in vivo treatment with 13,14-dihydro-PGE1 is of special interest, since LDL cholesterol accumulation in the arterial wall is considered a key event in atherogenesis.
Approval Year
Sample Use Guides
animals: donor animals and/or receiver animals were treated daily for 1 week with 13,14-dihydro-PGE1 (DIHYDROPROSTAGLANDIN E1), PGE1, 15-keto-PGE1, 15-keto-13,14-dihydro-PGE1, or the vehicle only, respectively. From the group of the receiver animals, a subgroup of 6 animals each was treated for the same period of time with either 13,14-dihydro-PGE1, PGE1, 15-keto-PGE1, 15-keto-13,14-dihydro-PGE1, or the vehicle. Immediately after the last administration of the respective PG or solvent, native blood from a donor rabbit was circulated [30 mL/min. under in vivo flow conditions (60 Hz)] over an arterial segment of a receiver animal.
Route of Administration:
Unknown
The actions of the in vivo metabolite of PGE1, 13,14-dihydro-PGE1 (DIHYDROPROSTAGLANDIN E1/ PGE0), on platelet and neutrophil (PMN) function and vessel tone were studied in vitro. PGE0 inhibited aggregation, ATP release and thromboxane generation by human platelets (IC50 10-100 nmol/l). The compound also inhibited superoxide anion generation and lysosomal enzyme release from human PMN. PGE0 was also potent relaxants of several arterial preparations in the rabbit at comparable concentrations.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:34:42 GMT 2025
by
admin
on
Mon Mar 31 23:34:42 GMT 2025
|
| Record UNII |
C1R6440YGW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID401317965
Created by
admin on Mon Mar 31 23:34:42 GMT 2025 , Edited by admin on Mon Mar 31 23:34:42 GMT 2025
|
PRIMARY | |||
|
C1R6440YGW
Created by
admin on Mon Mar 31 23:34:42 GMT 2025 , Edited by admin on Mon Mar 31 23:34:42 GMT 2025
|
PRIMARY | |||
|
161273
Created by
admin on Mon Mar 31 23:34:42 GMT 2025 , Edited by admin on Mon Mar 31 23:34:42 GMT 2025
|
PRIMARY | |||
|
19313-28-1
Created by
admin on Mon Mar 31 23:34:42 GMT 2025 , Edited by admin on Mon Mar 31 23:34:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
MAJOR
PLASMA
|
